TargetMol

Elesclomol

Product Code:
 
TAR-T6170
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6170-5mg5mg£98.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6170-1mL1 mL * 10 mM (in DMSO)£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6170-10mg10mg£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6170-25mg25mg£146.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6170-50mg50mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6170-100mg100mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6170-200mg200mg£266.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Elesclomol (STA-4783) is an effective oxidative stress inducer that elicits pro-apoptosis of tumor cells.
CAS:
488832-69-5
Formula:
C19H20N4O2S2
Molecular Weight:
400.52
Pathway:
Immunology/Inflammation; Cytoskeletal Signaling; NF-κb; Apoptosis; Metabolism
Purity:
0.9951
SMILES:
CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1
Target:
Apoptosis; HSP; Reactive Oxygen Species

References

Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580. Kirshner JR, et al. Mol Cancer Ther, 2008, 7(8), 2319-2327. Blackman RK, et al. PLoS One, 2012, 7(1), e29798. Bair JS, et al. J Am Chem Soc, 2010, 132(15, 5469-5478. Wu Z, Lin C, Zhang F, et al.TIGD1 Function as a Potential Cuproptosis Regulator Following a Novel Cuproptosis-Related Gene Risk Signature in Colorectal Cancer.Cancers.2023, 15(8): 2286.